Andy Billinton

966 total citations
22 papers, 673 citations indexed

About

Andy Billinton is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Andy Billinton has authored 22 papers receiving a total of 673 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Physiology, 8 papers in Molecular Biology and 8 papers in Pharmacology. Recurrent topics in Andy Billinton's work include Inflammatory mediators and NSAID effects (7 papers), Neuropeptides and Animal Physiology (5 papers) and Pain Mechanisms and Treatments (4 papers). Andy Billinton is often cited by papers focused on Inflammatory mediators and NSAID effects (7 papers), Neuropeptides and Animal Physiology (5 papers) and Pain Mechanisms and Treatments (4 papers). Andy Billinton collaborates with scholars based in United Kingdom, United States and Sweden. Andy Billinton's co-authors include Iain P. Chessell, Jon P. Hatcher, Stephen J. Medhurst, Julia H. White, Piers C. Emson, Richard L. M. Faull, Henry J. Waldvogel, Sharon Bingham, Gerard M.P. Giblin and Adrian Hall and has published in prestigious journals such as Journal of Neuroscience, The Journal of Comparative Neurology and Pain.

In The Last Decade

Andy Billinton

21 papers receiving 659 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andy Billinton United Kingdom	13	235	222	205	139	117	22	673
Silvia Pontis Italy	15	271 1.2×	228 1.0×	157 0.8×	73 0.5×	46 0.4×	30	745
George Grayson United States	11	239 1.0×	361 1.6×	231 1.1×	93 0.7×	119 1.0×	12	793
Margarita Suardíaz Spain	12	174 0.7×	240 1.1×	160 0.8×	143 1.0×	39 0.3×	17	591
S. Pérez-Torres Spain	9	563 2.4×	337 1.5×	129 0.6×	83 0.6×	52 0.4×	9	671
Zhi‐Wang Li China	16	367 1.6×	156 0.7×	224 1.1×	189 1.4×	25 0.2×	48	750
Shu-Tao Xie China	11	433 1.8×	62 0.3×	148 0.7×	253 1.8×	31 0.3×	20	757
Madhavi Pai United States	14	239 1.0×	499 2.2×	323 1.6×	297 2.1×	56 0.5×	22	906
Ann‐Cathrin Radesäter Sweden	11	429 1.8×	102 0.5×	264 1.3×	164 1.2×	43 0.4×	15	727
Anne‐Caroline Schmöle Germany	11	168 0.7×	258 1.2×	212 1.0×	65 0.5×	75 0.6×	14	564
Ju Shi United States	11	238 1.0×	160 0.7×	144 0.7×	179 1.3×	19 0.2×	15	787

Countries citing papers authored by Andy Billinton

Since Specialization

Citations

This map shows the geographic impact of Andy Billinton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Billinton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Billinton more than expected).

Fields of papers citing papers by Andy Billinton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Billinton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Billinton. The network helps show where Andy Billinton may publish in the future.

Co-authorship network of co-authors of Andy Billinton

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Billinton. A scholar is included among the top collaborators of Andy Billinton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Billinton. Andy Billinton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrison, David, Andy Billinton, Mark G. Bock, et al.. (2025). Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders. RSC Medicinal Chemistry. 16(11). 5318–5332.

Doedens, John R., Pamela J. Smolak, MyTrang Nguyen, et al.. (2024). Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework. ACS Pharmacology & Translational Science. 7(5). 1438–1456. 5 indexed citations

Ondrejčák, Tomáš, Igor Klyubin, Neng‐Wei Hu, et al.. (2023). Tau and Amyloid β Protein in Patient-Derived Aqueous Brain Extracts Act Concomitantly to Disrupt Long-Term Potentiationin Vivo. Journal of Neuroscience. 43(32). 5870–5879. 8 indexed citations

Hopkinson, Mark, et al.. (2021). Fracture-induced pain-like behaviours in a femoral fracture mouse model. Osteoporosis International. 32(11). 2347–2359. 12 indexed citations

Healy, Mark P., Andy Billinton, Iain P. Chessell, et al.. (2018). Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain. Bioorganic & Medicinal Chemistry Letters. 28(10). 1892–1896. 4 indexed citations

Billinton, Andy, Philip M. Newton, Chris J. Lloyd, et al.. (2017). [P1–074]: PRECLINICAL DISCOVERY AND DEVELOPMENT OF MEDI1814, A MONOCLONAL ANTIBODY SELECTIVELY TARGETING BETA‐AMYLOID 42 (Aβ42). Alzheimer s & Dementia. 13(7S_Part_5). 9 indexed citations

Ostenfeld, Thor, Michael B. Pomfret, Andy Billinton, et al.. (2017). [O2–09–02]: EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA‐AMYLOID 42 (Aβ42)‐SPECIFIC ANTIBODY, IN PATIENTS WITH MILD‐MODERATE ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 13(7S_Part_11). 5 indexed citations

Ondrejčák, Tomáš, et al.. (2016). MEDI1814, a high-affinity antibody directed to the C-terminus of Aßx-42 is able to rapidly prevent or reverse synaptic plasticity impairment in the rat hippocampus in vivo. Proceedings of The Physiological Society. 1 indexed citations

Chessell, Iain P., Amanda Dudley, & Andy Billinton. (2012). Biologics: the next generation of analgesic drugs?. Drug Discovery Today. 17(15-16). 875–879. 13 indexed citations

10.

Billinton, Andy, Susan H. Brown, A. R. Chowdhury, et al.. (2011). Discovery of a novel series of nonacidic benzofuran EP1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 21(14). 4343–4348. 13 indexed citations

11.

Beswick, Paul, Andy Billinton, David K. Dean, et al.. (2010). Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor. Bioorganic & Medicinal Chemistry Letters. 20(22). 6370–6374. 25 indexed citations

12.

Beswick, Paul, Andy Billinton, David K. Dean, et al.. (2010). Structure–activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. Bioorganic & Medicinal Chemistry Letters. 20(15). 4653–4656. 23 indexed citations

13.

Hall, Adrian, Andy Billinton, Susan H. Brown, et al.. (2009). Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP1 receptor antagonist for the treatment of inflammatory pain. Bioorganic & Medicinal Chemistry Letters. 19(9). 2599–2603. 15 indexed citations

14.

Medhurst, Stephen J., S D Collins, Andy Billinton, et al.. (2008). Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain. 138(1). 61–69. 71 indexed citations

15.

Hall, Adrian, Andy Billinton, Susan H. Brown, et al.. (2008). Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 18(8). 2684–2690. 23 indexed citations

16.

Hatcher, Jon P., Deborah J. Walker, Alastair Morrison, et al.. (2008). The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain. 139(1). 225–236. 221 indexed citations

17.

Hall, Adrian, Andy Billinton, Susan H. Brown, et al.. (2008). Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy. Bioorganic & Medicinal Chemistry Letters. 18(11). 3392–3399. 66 indexed citations

18.

Hall, Adrian, Andy Billinton, Susan H. Brown, et al.. (2008). Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 18(14). 4027–4032. 9 indexed citations

19.

Medhurst, Stephen J., Jon P. Hatcher, Christopher J. Hille, et al.. (2008). Activation of the α7-Nicotinic Acetylcholine Receptor Reverses Complete Freund Adjuvant–Induced Mechanical Hyperalgesia in the Rat Via a Central Site of Action. Journal of Pain. 9(7). 580–587. 34 indexed citations

20.

Waldvogel, Henry J., Andy Billinton, Julia H. White, Piers C. Emson, & Richard L. M. Faull. (2004). Comparative cellular distribution of GABA_A and GABA_B receptors in the human basal ganglia: Immunohistochemical colocalization of the α₁ subunit of the GABA_A receptor, and the GABA_BR1 and GABA_BR2 receptor subunits. The Journal of Comparative Neurology. 470(4). 339–356. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact